Editas Medicine

@editasmed

At Editas Medicine, we are pioneering the possible, harnessing the potential of CRISPR gene editing to develop medicines for people living with serious diseases

Cambridge, MA and Boulder, CO
Vrijeme pridruživanja: travanj 2014.

Tweetovi

Blokirali ste korisnika/cu @editasmed

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @editasmed

  1. 15. sij

    We're ready for day 3 at ! Tune in today at 10:30 a.m. PT (1:30 p.m. ET) as our CEO Cindy Collins takes the stage to share our recent progress and latest updates.

    Poništi
  2. 13. sij

    Learn more about our recent progress on developing in vivo and engineered cell medicines before our CEO, Cindy Collins, takes the stage later this week at the J.P. Morgan Healthcare Conference.

    Poništi
  3. 13. sij

    We just announced a collaboration with Sandhill Therapeutics to develop engineered cell medicines to treat cancer. Read more at:

    Poništi
  4. 9. sij

    We just announced some additions to our executive leadership team to support our long-term growth – Michelle Robertson joins us as Chief Financial Officer and manufacturing veteran Harry Gill joins as SVP, Operations. Read more at:

    Poništi
  5. 3. sij

    We're looking forward to . See you in San Francisco.

    Poništi
  6. 9. pro 2019.

    We just announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia at . Learn more at:

    Poništi
  7. 4. pro 2019.

    Check out some of the fundamental elements that make up our Inspiritas culture at Editas. And learn more at:

    Poništi
  8. 12. stu 2019.

    Today, we reported business highlights, results, and updates for the third quarter 2019. Learn more about our progress towards making medicines for people with serious diseases at:

    Poništi
  9. 12. stu 2019.

    We just announced an amended collaboration with Celgene to research, develop, and commercialize alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. Read more at:

    Poništi
  10. 4. stu 2019.

    We’re on an important journey to unlock the full potential of gene editing technology to make medicines for people living with serious diseases. Our work is driven by our dynamic, passionate, and diverse team. We are Editas.

    Poništi
  11. 1. ruj 2015.

    What if doctors could repair broken genes? See our op-ed!

    Poništi
  12. proslijedio/la je Tweet
    29. lip 2015.
    Poništi
  13. proslijedio/la je Tweet
    Poništi
  14. proslijedio/la je Tweet
    Poništi
  15. proslijedio/la je Tweet

    , of , will be speaking about at ! See the full agenda, here:

    Poništi
  16. proslijedio/la je Tweet
    5. velj 2015.

    No shocker but worth saying: "MA has more biotech employees than anywhere in US" CEO

    Poništi
  17. proslijedio/la je Tweet

    . emphasizes importance of basic research and R&D for

    Poništi
  18. proslijedio/la je Tweet
    5. velj 2015.

    MT Panel on techtrends in S. Inampudi J. Heppelmann K. Kleinfeld

    Poništi
  19. proslijedio/la je Tweet
    12. sij 2015.

    about to discuss gene therapy and genome editing with great co-panelists

    Poništi
  20. 8. sij 2015.

    congratulations to researcher Patrick Hsu for making Forbes 30 under 30!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·